TransCode Therapeutics

Historical price data

TransCode Therapeutics is a Boston-based biotech founded in 2016 with a mission to develop novel therapeutics for metastatic cancer, a historically underserved area of oncology. Its core achievement is the TTX platform, an iron oxide nanoparticle system designed to solve the persistent delivery challenge for oligonucleotides, enabling its lead candidate TTX-MC138 to target a key metastatic driver. The company's strategy involves advancing its RNA pipeline while leveraging the late-stage clinical assets from its acquisition of Polynoma LLC to create nearer-term value inflection points. As a public company, TransCode is in a capital-intensive clinical development stage, aiming to address a significant unmet medical need across multiple solid tumors.

Proprietary TTX platform utilizing tunable iron oxide nanoparticles designed for the systemic delivery of therapeutic oligonucleotides (e.g., anti-miRs, siRNA) to target cancer cells and metastases.

Faces limited direct competition in targeting miR-10b for metastasis but intense indirect competition from all effective metastatic cancer therapies. Its delivery platform competes in the crowded oligonucleotide delivery space, differentiated by its iron oxide nanoparticle design for solid tumors. The Polynoma vaccine competes with entrenched checkpoint inhibitors in the adjuvant melanoma market.